S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
Log in

Eiger BioPharmaceuticals Stock Forecast, Price & News

-0.51 (-4.66 %)
(As of 02/25/2021 12:00 AM ET)
Today's Range
Now: $10.44
50-Day Range
MA: $11.08
52-Week Range
Now: $10.44
Volume173,775 shs
Average Volume312,009 shs
Market Capitalization$339.63 million
P/E RatioN/A
Dividend YieldN/A
Eiger BioPharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide that has completed phase 2 clinical trial to treat post-bariatric hypoglycemia, as well as in phase 2 clinical trial for the treatment of congenital hyperinsulinism. The company is headquartered in Palo Alto, California.
Eiger BioPharmaceuticals logo


See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:EIGR
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$2.31 per share


Net Income$-70,250,000.00


Market Cap$339.63 million
Next Earnings Date3/12/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.61 out of 5 stars

Medical Sector

298th out of 1,957 stocks

Biological Products, Except Diagnostic Industry

38th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
-0.51 (-4.66 %)
(As of 02/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Eiger BioPharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

Is Eiger BioPharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Eiger BioPharmaceuticals stock.
View analyst ratings for Eiger BioPharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Eiger BioPharmaceuticals?

Wall Street analysts have given Eiger BioPharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eiger BioPharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Eiger BioPharmaceuticals' next earnings date?

Eiger BioPharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Eiger BioPharmaceuticals

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) released its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.52) EPS for the quarter, beating the Zacks' consensus estimate of ($0.61) by $0.09.
View Eiger BioPharmaceuticals' earnings history

How has Eiger BioPharmaceuticals' stock price been impacted by Coronavirus?

Eiger BioPharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EIGR shares have increased by 53.3% and is now trading at $10.44.
View which stocks have been most impacted by COVID-19

What price target have analysts set for EIGR?

2 analysts have issued 12 month target prices for Eiger BioPharmaceuticals' stock. Their forecasts range from $22.00 to $28.00. On average, they expect Eiger BioPharmaceuticals' share price to reach $25.00 in the next twelve months. This suggests a possible upside of 139.5% from the stock's current price.
View analysts' price targets for Eiger BioPharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Eiger BioPharmaceuticals' key executives?

Eiger BioPharmaceuticals' management team includes the following people:
  • Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 57, Pay $862.03k)
  • Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Independent Director (Age 58, Pay $53.5k)
  • Mr. Sriram Ryali M.B.A., Chief Financial Officer (Age 40, Pay $461.98k)
  • Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 50, Pay $417.8k)
  • Dr. Evan Loh, CEO of Paratek Pharmaceuticals & Director (Age 62, Pay $56k)
  • Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 60, Pay $55.5k)
  • Dr. Ingrid C. Choong, Sr. VP of Clinical Devel.
  • Mr. James P. Shaffer MBA, Chief Bus. Officer (Age 54)
  • Mr. Rich Franco M.B.A., Sr. VP & Progeria Program Lead
  • Dr. Colin Hislop, Sr. VP of Clinical & Devel. Operations (Age 63)

Who are some of Eiger BioPharmaceuticals' key competitors?

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

What is Eiger BioPharmaceuticals' stock symbol?

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.30%), Northern Trust Corp (1.33%), P.A.W. Capital Corp (1.23%), Laurion Capital Management LP (0.77%), Trellus Management Company LLC (0.63%) and JPMorgan Chase & Co. (0.63%). Company insiders that own Eiger BioPharmaceuticals stock include Eldon C Mayer III, Jeffrey S Glenn, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz.
View institutional ownership trends for Eiger BioPharmaceuticals

Which major investors are selling Eiger BioPharmaceuticals stock?

EIGR stock was sold by a variety of institutional investors in the last quarter, including Caxton Corp, DRW Securities LLC, Barclays PLC, and Russell Investments Group Ltd..
View insider buying and selling activity for Eiger BioPharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Eiger BioPharmaceuticals stock?

EIGR stock was acquired by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, BlackRock Inc., State of Wisconsin Investment Board, Squarepoint Ops LLC, P.A.W. Capital Corp, Dfpg Investments LLC, Engineers Gate Manager LP, and Nuveen Asset Management LLC. Company insiders that have bought Eiger BioPharmaceuticals stock in the last two years include Eldon C Mayer III, Jeffrey S Glenn, Sriram Ryali, Stephana Eilene Patton, and Thomas John Dietz.
View insider buying and selling activity for Eiger BioPharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eiger BioPharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $10.44.

How much money does Eiger BioPharmaceuticals make?

Eiger BioPharmaceuticals has a market capitalization of $339.63 million. The biotechnology company earns $-70,250,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis.

How many employees does Eiger BioPharmaceuticals have?

Eiger BioPharmaceuticals employs 29 workers across the globe.

What is Eiger BioPharmaceuticals' official website?

The official website for Eiger BioPharmaceuticals is www.eigerbio.com.

Where are Eiger BioPharmaceuticals' headquarters?

Eiger BioPharmaceuticals is headquartered at 2155 PARK BOULEVARD, PALO ALTO CA, 94306.

How can I contact Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]

This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.